Using Skin Biomarkers to Address Placebo Response & Endpoint Variability to Improve Signal Detection in AD, HS & Psoriasis Trials
- Understanding rising placebo responses across EASI, IGA and HiSCR-based assessments, reducing interpretive noise, to improve confidence in whether an active therapy is truly effective or underpowered by endpoint variability
- Integrating objective measures such as tape stripping, blood biomarkers, imaging and AI-enabled lesion assessment, capturing earlier biological activity and target engagement, to strengthen early efficacy readouts and support go/no-go decision-making
- Designing trials around disease heterogeneity and patient fluctuation patterns, distinguishing chronic from rapid-cycling disease activity, to reduce placebo interference, improve endpoint timing and increase the likelihood of demonstrating meaningful treatment benefit